ImmunityBioIBRX
IBRX
About: ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
Employees: 680
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
120% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 20
71% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 41
11% more funds holding
Funds holding: 180 [Q3] → 199 (+19) [Q4]
1.45% more ownership
Funds ownership: 9.86% [Q3] → 11.32% (+1.45%) [Q4]
17% less call options, than puts
Call options by funds: $8.21M | Put options by funds: $9.86M
17% less capital invested
Capital invested by funds: $256M [Q3] → $212M (-$43.8M) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$8
219%
upside
Avg. target
$15.33
511%
upside
High target
$30
1,095%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Andrew Fein 32% 1-year accuracy 113 / 354 met price target | 219%upside $8 | Buy Reiterated | 28 Apr 2025 |
D. Boral Capital Jason Kolbert 28% 1-year accuracy 107 / 376 met price target | 1,095%upside $30 | Buy Maintained | 28 Apr 2025 |
HC Wainwright & Co. Andres Maldonado 28% 1-year accuracy 15 / 53 met price target | 219%upside $8 | Buy Reiterated | 16 Apr 2025 |
Financial journalist opinion
Based on 8 articles about IBRX published over the past 30 days
Negative
Seeking Alpha
1 day ago
ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish
ImmunityBio, Inc.'s stock has significantly declined despite my previous "Buy" ratings, primarily due to a $100m fundraising and market selloff in December. Founder Dr. Patrick Soon-Shiong's vision for Anktiva as a groundbreaking cancer therapy remains strong, with promising data and potential label expansions in multiple oncology fields. Short-term concerns include high cash burn, premium pricing, and BCG shortages, which may lead to a stock selloff after Q1 earnings.
Neutral
Business Wire
2 days ago
Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced positive long-term results from its QUILT-3.032 study of ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Guérin (BCG) for the treatment of adult patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS), with or without papillary disease. The findings were shared during an oral presentation at the American Urological.
Neutral
Business Wire
1 week ago
ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, will announce new clinical findings for ANKTIVA® (nogapendekin alfa inbakicept-pmln) in non-muscle invasive bladder cancer carcinoma in situ (NMIBC CIS) and updated data on papillary disease without CIS at the American Urological Association Annual Meeting (AUA 2025) in Las Vegas, April 26-29. The company will also host an educational and peer-networking event to discuss ImmunityBio's approa.
Neutral
Business Wire
2 weeks ago
ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has completed multiple submissions to the FDA including an sBLA for BCG-unresponsive NMIBC in papillary disease and an EAP for ANKTIVA® (nogapendekin alfa inbakicept-pmln) for the treatment of lymphopenia. Supplemental Biologics License Application (sBLA): In Q1, ImmunityBio completed the submission to the FDA of an sBLA for the use of ANKTIVA plus BCG in BCG-unrespon.
Neutral
Business Wire
3 weeks ago
ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced that it has executed financing to provide further working capital and support its ongoing business operations. The Company entered into a securities purchase agreement for a registered direct offering with a single institutional investor, providing for the issuance of common stock of ImmunityBio as well as warrants for the purchase of additional shares of common stock of Immu.
Neutral
PRNewsWire
3 weeks ago
Pomerantz LLP and Holzer & Holzer, LLC Announce Pendency and Proposed Settlement of Class Action Involving Purchases of ImmunityBio, Inc. Securities
SAN DIEGO , April 7, 2025 /PRNewswire/ -- UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF CALIFORNIA IN RE IMMUNITYBIO, INC. SECURITIES LITIGATION No.
Neutral
Business Wire
3 weeks ago
ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced details about its Investor Day program to be held on Tuesday, April 15, 2025, at 10:00 am PDT. The program will include an in-depth update on the company's business operations, U.S. and global regulatory advances of its clinical-stage products, with fireside chats hosted by Dr. Patrick Soon-Shiong and key opinion leaders involved in the company's research programs. The discus.
Positive
Seeking Alpha
3 weeks ago
ImmunityBio: Taking Care Of Business
ImmunityBio, Inc.'s recent progress on Anktiva and rBCG, including FDA submissions and collaborations, positions the company for significant revenue growth despite current financial challenges. The severe BCG shortage impacts Anktiva's growth, but ImmunityBio's rBCG efforts could fill the supply gap and potentially redefine NMIBC treatment. Despite strong commercial momentum, ImmunityBio's financial health remains a concern, with a quarterly cash burn rate of $104.4M and a cash runway of less than four months.
Neutral
Business Wire
1 month ago
ImmunityBio to Host Investor Day
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, invites current and prospective investors to its Investor Day program to be held on Tuesday, April 15, 2025, at 10:00 am PDT. The program will include an in-depth update on the company's business operations and recent R&D advancements. Key timelines for catalysts of product candidates will be presented, along with a discussion of ongoing clinical trials. “ImmunityBio commenced 2025 with.
Neutral
Business Wire
1 month ago
ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation's largest independent providers of urology and related specialty services, is one of the first providers to participate in ImmunityBio's Expanded Access Program (EAP) for recombinant Bacillus Calmette-Guérin (rBCG) to address the current shortage of TICE® BCG in the U.S. “The shortage of BCG has real consequences, especially in many ru.
Charts implemented using Lightweight Charts™